Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials • Transportation, E-Commerce & Mechanical Systems
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Hisamitsu Pharmaceutical Co., Inc. has 6 pending office actions in Biotechnology & Pharmaceuticals. The matters are handled by 6 distinct examiners in 6 distinct art units, showing assignment spread across the portfolio rather than concentration in one examination group.
HUSON, MONICA ANNE is the busiest examiner, with 1 pending matter. Because no examiner handles more than that matter in the supplied profile, prosecution planning is better organized around consistent substantive positions and technology-specific support than around a dominant examiner relationship.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (60%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUSON, MONICA ANNE | 1 | 79.6% | +13.5% |
| CHI, AMANDA LYNN | 1 | — | — |
| KUMAR, RAKESH | 1 | 57.2% | +28.2% |
| SOROUSH, LAYLA | 1 | 40.5% | +43.4% |
| NGUYEN, NGOC-ANH THI | 1 | 30.3% | +50.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19169280 | MICRONEEDLE SHEET PRODUCTION METHOD AND MICRONEEDLE SHEET | HUSON, MONICA ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270760 | PACKAGING BAG AND PATCH PACKAGING PRODUCT | KUMAR, RAKESH | 14d |
| 19169280 | MICRONEEDLE SHEET PRODUCTION METHOD AND MICRONEEDLE SHEET | HUSON, MONICA ANNE | — |
| 17796921 | DICLOFENAC SODIUM CONTAINING PATCH | SOROUSH, LAYLA | — |
| 17433289 | TRANSDERMAL PATCH | NGUYEN, NGOC-ANH THI | — |
| Art Unit | Apps |
|---|---|
| 1742 | 1 |
| 1613 | 1 |
| 3651 | 1 |
| 1622 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19169280 | MICRONEEDLE SHEET PRODUCTION METHOD AND MICRONEEDLE SHEET | HUSON, MONICA ANNE | 1742 | §102§103 | Non-Final OA | — | Pending | Apr 03, 2025 |
| 18705656 | ADHESIVE PATCH WITH COVER MATERIAL | CHI, AMANDA LYNN | 1613 | §103 | Final Rejection | 16d | Pending | Apr 29, 2024 |
| 18270760 | PACKAGING BAG AND PATCH PACKAGING PRODUCT | KUMAR, RAKESH | 3651 | §103 | Final Rejection | 14d | Pending | Jul 03, 2023 |
| 17796921 | DICLOFENAC SODIUM CONTAINING PATCH | SOROUSH, LAYLA | 1622 | §103DP | Non-Final OA | — | Pending | Aug 02, 2022 |
| 17433289 | TRANSDERMAL PATCH | NGUYEN, NGOC-ANH THI | 1615 | §103 | Final Rejection | — | Pending | Aug 24, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHisamitsu Pharmaceutical Co., Inc. has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Monica Anne Huson has the most, with 1 of Hisamitsu Pharmaceutical Co., Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
